Warning! GuruFocus detected
1 Severe warning sign
with CNTX.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Context Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US21077P1084
Description
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 431.19 | |||||
| Equity-to-Asset | 0.97 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 48.1 | |||||
| 3-Year EPS without NRI Growth Rate | 43.9 | |||||
| 3-Year FCF Growth Rate | 46 | |||||
| 3-Year Book Growth Rate | -25.1 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 69.75 | |||||
| 9-Day RSI | 60.52 | |||||
| 14-Day RSI | 54.9 | |||||
| 3-1 Month Momentum % | -29.17 | |||||
| 6-1 Month Momentum % | -57.8 | |||||
| 12-1 Month Momentum % | -35.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 35.62 | |||||
| Quick Ratio | 35.62 | |||||
| Cash Ratio | 34.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -67.5 | |||||
| Shareholder Yield % | -167.44 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -44.46 | |||||
| ROA % | -42.52 | |||||
| ROIC % | -3341.22 | |||||
| 3-Year ROIIC % | -1577.96 | |||||
| ROC (Joel Greenblatt) % | -11050.22 | |||||
| ROCE % | -49.74 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.68 | |||||
| Price-to-Tangible-Book | 0.68 | |||||
| EV-to-EBIT | 0.56 | |||||
| EV-to-Forward-EBIT | -0.29 | |||||
| EV-to-EBITDA | 0.56 | |||||
| EV-to-Forward-EBITDA | -1.35 | |||||
| EV-to-FCF | 2.54 | |||||
| Price-to-Net-Current-Asset-Value | 0.68 | |||||
| Price-to-Net-Cash | 0.71 | |||||
| Earnings Yield (Greenblatt) % | 178.57 | |||||
| FCF Yield % | -18.8 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CNTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Context Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.49 | ||
| Beta | 2.28 | ||
| 3-Year Sharpe Ratio | 0.24 | ||
| 3-Year Sortino Ratio | 0.42 | ||
| Volatility % | 77.66 | ||
| 14-Day RSI | 54.9 | ||
| 14-Day ATR ($) | 0.093677 | ||
| 20-Day SMA ($) | 0.791845 | ||
| 12-1 Month Momentum % | -35.36 | ||
| 52-Week Range ($) | 0.64 - 2.75 | ||
| Shares Outstanding (Mil) | 89.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Context Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Context Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Context Therapeutics Inc Frequently Asked Questions
What is Context Therapeutics Inc(CNTX)'s stock price today?
The current price of CNTX is $0.86. The 52 week high of CNTX is $2.75 and 52 week low is $0.64.
When is next earnings date of Context Therapeutics Inc(CNTX)?
The next earnings date of Context Therapeutics Inc(CNTX) is 2025-05-30 Est..
Does Context Therapeutics Inc(CNTX) pay dividends? If so, how much?
Context Therapeutics Inc(CNTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers